OPKO Health (OPK) Competitors $1.41 +0.03 (+2.17%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.40 -0.01 (-1.06%) As of 08/22/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OPK vs. LGND, FOLD, BCRX, CLDX, NVAX, INVA, DVAX, MNKD, GERN, and ZBIOShould you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), Geron (GERN), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. OPKO Health vs. Its Competitors Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Novavax Innoviva Dynavax Technologies MannKind Geron Zenas BioPharma OPKO Health (NASDAQ:OPK) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings. Is OPK or LGND more profitable? OPKO Health has a net margin of -26.68% compared to Ligand Pharmaceuticals' net margin of -40.44%. Ligand Pharmaceuticals' return on equity of -9.21% beat OPKO Health's return on equity.Company Net Margins Return on Equity Return on Assets OPKO Health-26.68% -13.17% -8.28% Ligand Pharmaceuticals -40.44%-9.21%-8.09% Which has more risk & volatility, OPK or LGND? OPKO Health has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Do insiders and institutionals hold more shares of OPK or LGND? 64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor OPK or LGND? In the previous week, Ligand Pharmaceuticals had 12 more articles in the media than OPKO Health. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 0 mentions for OPKO Health. OPKO Health's average media sentiment score of 1.68 beat Ligand Pharmaceuticals' score of 1.20 indicating that OPKO Health is being referred to more favorably in the media. Company Overall Sentiment OPKO Health Very Positive Ligand Pharmaceuticals Positive Do analysts rate OPK or LGND? OPKO Health presently has a consensus target price of $2.75, suggesting a potential upside of 95.04%. Ligand Pharmaceuticals has a consensus target price of $157.00, suggesting a potential downside of 1.31%. Given OPKO Health's higher probable upside, equities analysts plainly believe OPKO Health is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OPKO Health 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, OPK or LGND? Ligand Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOPKO Health$713.10M1.57-$53.22M-$0.25-5.64Ligand Pharmaceuticals$167.13M18.66-$4.03M-$4.00-39.77 SummaryOPKO Health beats Ligand Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get OPKO Health News Delivered to You Automatically Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPK vs. The Competition Export to ExcelMetricOPKO HealthMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12B$7.12B$5.82B$9.76BDividend YieldN/A1.28%4.40%4.04%P/E Ratio-5.6427.4531.3826.05Price / Sales1.5775.21472.41122.40Price / Cash20.5022.3525.7828.78Price / Book0.714.949.526.07Net Income-$53.22M$176.42M$3.26B$265.39M7 Day Performance2.92%1.45%2.14%2.00%1 Month Performance0.71%-1.85%3.22%0.46%1 Year Performance-12.42%9.53%30.19%18.88% OPKO Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPKOPKO Health4.4454 of 5 stars$1.41+2.2%$2.75+95.0%-12.4%$1.12B$713.10M-5.642,997Positive NewsLGNDLigand Pharmaceuticals4.0957 of 5 stars$153.26+1.4%$157.00+2.4%+53.2%$3.00B$187.58M-38.3280News CoveragePositive NewsShort Interest ↓FOLDAmicus Therapeutics4.3436 of 5 stars$7.41+0.1%$16.22+118.9%-35.3%$2.28B$571.16M-61.74480News CoveragePositive NewsBCRXBioCryst Pharmaceuticals4.1944 of 5 stars$8.38+0.1%$16.70+99.3%+5.7%$1.76B$450.71M-46.55530Positive NewsCLDXCelldex Therapeutics1.5927 of 5 stars$24.48-4.0%$51.75+111.4%-39.6%$1.63B$7.02M-8.13150News CoverageAnalyst ForecastNVAXNovavax4.6153 of 5 stars$9.71+1.4%$15.86+63.3%-34.6%$1.58B$1.08B4.261,990News CoverageAnalyst ForecastINVAInnoviva4.5145 of 5 stars$20.78-0.7%$42.75+105.7%+6.9%$1.31B$358.71M67.03100News CoverageAnalyst DowngradeDVAXDynavax Technologies4.5033 of 5 stars$10.76-0.3%$24.33+126.1%-8.6%$1.26B$277.25M-23.39350News CoverageAnalyst ForecastMNKDMannKind3.3291 of 5 stars$3.81+2.1%$9.71+155.0%-23.5%$1.17B$285.50M34.64400GERNGeron2.9695 of 5 stars$1.44-0.7%$4.19+190.8%-67.8%$918.74M$164.45M-11.08229News CoverageGap UpZBIOZenas BioPharma1.4786 of 5 stars$17.28+2.7%$36.67+112.2%N/A$727.66M$5M-4.87N/A Related Companies and Tools Related Companies LGND Competitors FOLD Competitors BCRX Competitors CLDX Competitors NVAX Competitors INVA Competitors DVAX Competitors MNKD Competitors GERN Competitors ZBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPK) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OPKO Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OPKO Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access